ImmuONE awarded Innovate UK funding

Reading Time
10 minutes

ImmuONE won their bid in a competitive funding round from Innovate UK to commercialise their first product in the pipeline, ImmuLUNG™. The technology provides an accurate physiological and functional representation of the human alveolus, providing a reliable platform to assess the safety of inhaled compounds.

Add a Comment

To sum up, relevant strong micro-physiological models will improve R&D efficiency and reduce drug attrition. Micro-physiological systems show great promise once fully developed. Like most medical devices, the models are challenged and present many obstacles.

As the system is small and intricate, it takes longer for the models to be optimised. Initially the availability of MPS models for drug assessment will improve human safety whilst keeping controversies at bay.

By establishing sustainable MPS banks, relevant quantitative data can be reproduced and applied to various studies. The life sciences community need to collaborate and communicate with each other to generate quality systems efficiently.


Scroll to Top